At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...

Arcus Biosciences (NYSE:RCUS) reported positive late stage efficacy results for casdatifan, its investigational HIF-2a inhibitor, in late line renal cell carcinoma. The company released biomarker ...

The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...

Earlier analyses demonstrated strong local tumor control, with nearly nine in 10 patients remaining free of recurrence at ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases ...

The combination of fruquintinib and serplulimab has shown antitumor activity in treatment-naive advanced non-clear cell renal cell carcinoma.

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

KEY + WEL as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death Compared to KEYTRUDA Mono in Certain Patients ...

Combination cut risk of recurrence or death by 28% in patients at high risk of relapse ...

Study of late toxicities of chemotherapy regimens in testicular cancer survivors shows that higher cisplatin doses link renal impairment to increased heart health risks.

Doctors emphasised that timely diagnosis and proper treatment can save over 80 per cent of children affected by cancer.

Findings presented at the 2026 ASCO GU Symposium show that combinatorial therapies may provide new treatment options for patients with renal cell carcinoma or muscle-invasive bladder cancer.